SCHEMBL7125887

SCHEMBL7125887

CCCCOc1cccc(Sc2nc(N)nc3c2ncn3CCOCP(=O)(O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.45
SLC22A6 Q4U2R8 1/20 0.45
SLC29A1 Q99808 2/20 0.42
CYP2C19 P33261 2/20 0.42
POLB P06746 4/20 0.41
PNP P00491 2/20 0.40
DHFR P00374 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
HIF1A Q16665 1/20 0.38
POLA1 P09884 1/20 0.38
POLG P54098 1/20 0.38
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125992 0.96 FGFR1 (0.46) FGFR1SLC22A6SLC29A1CYP2C19POLB
SCHEMBL7126838 0.93 FGFR1 (0.46) FGFR1SLC22A6SLC29A1CYP2C19POLB
SCHEMBL7121312 0.91 FGFR1 (0.47) FGFR1SLC22A6CYP2C19POLBPNP
SCHEMBL7119964 0.91 FGFR1 (0.48) FGFR1SLC22A6SLC29A1CYP2C19POLB
SCHEMBL7130456 0.89 FGFR1 (0.44) FGFR1SLC22A6SLC29A1CYP2C19POLB
SCHEMBL7128849 0.89 FGFR1 (0.45) FGFR1SLC22A6SLC29A1CYP2C19POLB
SCHEMBL7773508 0.87 SLC29A1 (0.45) SLC29A1CYP2C19DHFRCYP1A2CYP3A4
SCHEMBL7128447 0.87 FGFR1 (0.48) FGFR1SLC22A6SLC29A1CYP2C19POLB
SCHEMBL7130409 0.86 CYP3A4 (0.47) SLC29A1PNPCYP1A2CYP3A4CYP2D6
SCHEMBL6846450 0.86 FGFR1 (0.49) FGFR1SLC22A6SLC29A1CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109498-A1 Antiviral agent for drug-resistant virus MITSUBISHI PHARMA CORPORATION (JP) 2003-06-12 US claimed
US-20030109498-A1 Antiviral agent for drug-resistant virus MITSUBISHI PHARMA CORPORATION (JP) 2003-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109498-A1 Antiviral agent for drug-resistant virus TPMT, MTAP, TYMP FGFR1 1401/4885SLC22A6 399/4885SLC29A1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.